The immunizing effect and reactogenicity of two live attenuated mumps virus vaccines in Swedish schoolchildren.
An evaluation of the seroconversion and booster effects after vaccination with two different mumps vaccines, the Urabe Am 9 strain and the Jeryl Lynn strain, was carried out in schoolchildren. Four hundred and fifty-four schoolchildren aged 11 to 12 years with no previous history of mumps or mumps vaccination were enrolled for the study. The antibody responses were measured by serum neutralization (SN) and haemolysis-in-gel (HIG) tests. Of the 454 subjects, 130 were found to be initially seronegative. Two lots of different strengths of each vaccine were used to evaluate the relationships. The Urabe Am 9 vaccine lots had infectivity titres of 100 000 and 19 000 TCID50 per dose and the Jeryl Lynn vaccine titres of 59 000 and 28 000 TCID50 per dose. Only slight differences in seroconversion rates were seen between the lots. The overall seroconversion rate, measured by SN, was 94% for the Urabe Am 9 vaccine and 91% for the Jeryl Lynn vaccine, whereas the geometric mean titre for virus-neutralizing antibody in seroconverting children was 7.4 with the Urabe Am 9 vaccine and 10.7 with the Jeryl Lynn vaccine. In children who were seropositive prior to vaccination, a marked rise in antibody titre was found 8 weeks after vaccine injection indicating a booster effect. The miscellaneous post-vaccination side-effects were mild and inconsequential.
D000914:Antibodies, Viral / Q000032:analysis*; D002648:Child; D006801:Humans; D009108:Mumps Vaccine / Q000009:adverse effects / Q000276:immunology*; D009109:Mumps virus / Q000276:immunology; D009500:Neutralization Tests; D013548:Sweden; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology*
D000914:Antibodies, Viral; D009108:Mumps Vaccine; D014613:Vaccines, Attenuated